SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001609351-18-000037
Filing Date
2018-04-20
Accepted
2018-04-20 16:45:17
Documents
4
Effectiveness Date
2018-04-20

Document Format Files

Seq Description Document Type Size
1 DEFA14A a208proxy14a.htm DEFA14A 32132
2 proxy2018notice01.jpg GRAPHIC 237625
3 proxy2018notice03.jpg GRAPHIC 67052
4 proxy2018regnoticecardfinalp.jpg GRAPHIC 137279
  Complete submission text file 0001609351-18-000037.txt   642237
Mailing Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Business Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 888-772-7560
Spark Therapeutics, Inc. (Filer) CIK: 0001609351 (see all company filings)

IRS No.: 462654405 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36819 | Film No.: 18767246
SIC: 2836 Biological Products, (No Diagnostic Substances)